AU505940B2 - Stable cefazolin suspension - Google Patents

Stable cefazolin suspension

Info

Publication number
AU505940B2
AU505940B2 AU11868/76A AU1186876A AU505940B2 AU 505940 B2 AU505940 B2 AU 505940B2 AU 11868/76 A AU11868/76 A AU 11868/76A AU 1186876 A AU1186876 A AU 1186876A AU 505940 B2 AU505940 B2 AU 505940B2
Authority
AU
Australia
Prior art keywords
cefazolin
suspension
stable
stable cefazolin
cefazolin suspension
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU11868/76A
Other languages
English (en)
Other versions
AU1186876A (en
Inventor
M Bornstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU1186876A publication Critical patent/AU1186876A/en
Application granted granted Critical
Publication of AU505940B2 publication Critical patent/AU505940B2/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU11868/76A 1975-04-28 1976-03-11 Stable cefazolin suspension Expired AU505940B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
USUS573,283 1975-04-28
US05/573,283 US4029782A (en) 1975-04-28 1975-04-28 Cefazolin suspension for parenteral administration

Publications (2)

Publication Number Publication Date
AU1186876A AU1186876A (en) 1977-09-15
AU505940B2 true AU505940B2 (en) 1979-12-06

Family

ID=24291351

Family Applications (1)

Application Number Title Priority Date Filing Date
AU11868/76A Expired AU505940B2 (en) 1975-04-28 1976-03-11 Stable cefazolin suspension

Country Status (8)

Country Link
US (1) US4029782A (https=)
JP (1) JPS51130522A (https=)
AU (1) AU505940B2 (https=)
BE (1) BE841157A (https=)
DE (1) DE2618422A1 (https=)
FR (1) FR2309211A1 (https=)
GB (1) GB1546479A (https=)
ZA (1) ZA761476B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4344934A (en) * 1978-11-20 1982-08-17 American Home Products Corporation Therapeutic compositions with enhanced bioavailability
GB8322364D0 (en) * 1983-08-19 1983-09-21 May & Baker Ltd Compositions of matter
US6660049B1 (en) 1996-07-31 2003-12-09 Natural Soda Aala, Inc. Process for control of crystallization of inorganics from aqueous solutions
US6495164B1 (en) * 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
RU2310450C2 (ru) * 2002-10-25 2007-11-20 Пфайзер Продактс Инк. Новые депо-препараты для инъекций

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3297692A (en) * 1961-04-03 1967-01-10 Lilly Co Eli 7-alkylmercaptoacetamidocephalosporanic acid
GB1051746A (https=) * 1961-12-22
US3293133A (en) * 1963-04-24 1966-12-20 Squibb & Sons Inc Method of imparting color to pharmaceutical solutions
CH557381A (de) * 1967-04-15 1974-12-31 Fujisawa Pharmaceutical Co Verfahren zur herstellung von (delta)3-cephemverbindungen.
GB1244501A (en) * 1968-03-09 1971-09-02 Aspro Nicholas Ltd Heterocyclic amines
US3678163A (en) * 1969-06-02 1972-07-18 Merck & Co Inc Stabilized aqueous suspension of calcium (-) (cis-1,2-epoxypropyl)-phosphonate
US3897423A (en) * 1973-03-05 1975-07-29 Squibb & Sons Inc Amino substituted acylthio cephalosporins

Also Published As

Publication number Publication date
ZA761476B (en) 1977-10-26
BE841157A (fr) 1976-10-27
AU1186876A (en) 1977-09-15
DE2618422A1 (de) 1976-11-11
FR2309211B1 (https=) 1979-03-23
JPS51130522A (en) 1976-11-12
GB1546479A (en) 1979-05-23
US4029782A (en) 1977-06-14
FR2309211A1 (fr) 1976-11-26

Similar Documents

Publication Publication Date Title
AU1108376A (en) Polyhemoglobin
AU1025376A (en) Pourer-stopper
AU1006976A (en) Inhilator
AU1670276A (en) Tetrahydro-isoquinolines
AU1230276A (en) Amidinoureas
AU1230176A (en) Imidinoureas
AU1441776A (en) Thieno-pyridines
AU1373876A (en) Bottlecap
AU501791B2 (en) Antiroll suspension
AU1667476A (en) Chroman-4-ones
AU1128976A (en) Magneto-alternator
AU1637076A (en) Banjo-shaped axle-casing
AU1710076A (en) Dihydrooxadiazinones
AU1417076A (en) Propargyl-2 phenylamino-2-impazolines
AU1565576A (en) L- pyroglutamyl-l-prolinamide
AU501362B2 (en) Cephalosporins
AU506584B2 (en) Cephalosporins
AU505940B2 (en) Stable cefazolin suspension
AU1408076A (en) Lysolipin Antibioties
AU1191776A (en) Fluoro-prostaglandins
AU501766B2 (en) Cephalosporins
AU1393076A (en) Dihydromocimycin
AU1398876A (en) Aryl-di-thioureas
AU505141B2 (en) Cephalosporins
AU1625476A (en) Aryltetralins